医学
放化疗
肿瘤科
抗体
内科学
食管鳞状细胞癌
免疫检查点
免疫疗法
癌症研究
癌
化疗
免疫学
癌症
作者
Rong Yu,Wenqing Wang,Tao Li,Jiancheng Li,Kuaile Zhao,Weihu Wang,Long Liang,Haishan Wu,Ta-shan Ai,Wei Huang,Liyun Li,Wentao Yu,Chenlu Wei,Yidi Wang,Wei Shen,Zefen Xiao
出处
期刊:Future Oncology
[Future Medicine]
日期:2021-11-01
卷期号:17 (31): 4081-4089
被引量:42
标识
DOI:10.2217/fon-2021-0632
摘要
Definitive chemoradiotherapy is the standard of care for inoperable locoregionally advanced esophageal squamous cell carcinoma (ESCC). Immune checkpoint inhibitors such as anti-PD-1/PD-L1 antibodies have led to a paradigm shift in advanced, metastatic ESCC treatment; however, the effect of incorporating checkpoint inhibitors in the definitive management of ESCC is unclear. Tislelizumab is an anti-PD-1 antibody specifically engineered to minimize FcɣR binding on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. The RATIONALE 311 study described here (BGB-A317-311; NCT03957590) is a registrational multicenter, double-blind, placebo-controlled, randomized, Phase III clinical trial designed to evaluate the efficacy and safety of tislelizumab combined with concurrent chemoradiotherapy in patients with inoperable localized ESCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI